1. Volume 65, Issue 3, Pages 197-202 (March 2015)
Major bleeding complications related to combined antithrombotic therapy in atrial fibrillation patients 12 months after coronary artery stenting 
Hideki Kawai, MD, PhD, Eiichi Watanabe, MD, PhD, Mayumi Yamamoto, MD, Hiroto Harigaya, MD, PhD, Kan Sano, MD, PhD, Hidemaro Takatsu, MD, Takashi Muramatsu, MD, PhD, Hiroyuki Naruse, MD, PhD, Yoshihiro Sobue, MD, PhD, Sadako Motoyama, MD, PhD, Masayoshi Sarai, MD, PhD, Hiroshi Takahashi, BSc, Tomoharu Arakawa, MD, PhD, Shino Kan, MD, Atsushi Sugiura, MD, PhD, Toyoaki Murohara, MD, PhD, Yukio Ozaki, MD, PhD, FJCC 
Journal of Cardiology 
Volume 65, Issue 3, Pages (March 2015)
DOI: /j.jjcc
Copyright © 2014 Japanese College of Cardiology Terms and Conditions

2. Fig. 1
The gray bars show the number of patients with SAPT plus warfarin, DAPT, and DAPT plus warfarin at discharge of stenting (0M). The bars at 12M show the antithrombotic treatment 12 months after stenting, divided into three colors by their outcomes. CAE, composite of adverse events; DAPT, dual antiplatelet therapy; M, months; SAPT, single antiplatelet therapy. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.)
Journal of Cardiology  , DOI: ( /j.jjcc )
Copyright © 2014 Japanese College of Cardiology Terms and Conditions

3. Fig. 2
Cumulative incidence of (A) Thrombolysis in Myocardial Infarction major bleeding among all groups; (B) composite of adverse events among all groups. DAPT, dual antiplatelet therapy; SAPT, single antiplatelet therapy; W, warfarin.
Journal of Cardiology  , DOI: ( /j.jjcc )
Copyright © 2014 Japanese College of Cardiology Terms and Conditions